Arcutis Biotherapeutics (ARQT) Asset Utilization Ratio (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Asset Utilization Ratio of 0.93 for Q1 2026, up 54.46% year-over-year from 0.6 in Q1 2025, and little changed quarter-over-quarter from 0.93 in Q4 2025.
Arcutis Biotherapeutics (ARQT) Asset Utilization Ratio (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Asset Utilization Ratio history runs 5 years deep, the most recent figure standing at 0.93 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 54.46% year-over-year to 0.93; the TTM figure through Mar 2026 stood at 0.93 (up 54.46% YoY), while the FY2025 annual figure was 0.96, up 99.35% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.93, roughly flat from 0.93 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.93 in Q1 2026, with the low at 0.0 in Q3 2022.
- The 5-year median for Asset Utilization Ratio is 0.29 (2024), against an average of 0.39.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio surged 8745.41% in 2023, then soared 49.95% in 2024.
- Arcutis Biotherapeutics' Asset Utilization Ratio stood at 0.01 in 2022, then surged by 3572.16% to 0.28 in 2023, then jumped by 49.95% to 0.42 in 2024, then jumped by 119.66% to 0.93 in 2025, then climbed by 0.03% to 0.93 in 2026.
- Business Quant data shows ARQT's Asset Utilization Ratio at 0.93 in Q1 2026, 0.93 in Q4 2025, and 0.87 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 0.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.98 |
| Mar 31, 2026 | 0.93 |
| Dec 31, 2025 | 0.93 |
| Sep 30, 2025 | 0.87 |
| Jun 30, 2025 | 0.75 |
| Mar 31, 2025 | 0.60 |
| Dec 31, 2024 | 0.42 |
| Sep 30, 2024 | 0.32 |
| Jun 30, 2024 | 0.29 |
| Mar 31, 2024 | 0.26 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | 0.16 |
| Jun 30, 2023 | 0.03 |
| Mar 31, 2023 | 0.02 |
| Dec 31, 2022 | 0.01 |
| Sep 30, 2022 | 0.00 |